Cannabis Market News: CV Sciences Diversifies Portfolio; CBDistillery’s CBN Entry; More

CV Sciences aims to offset COVID-19 impacts with its new Happy Lane CBD product line, targeted to the value retail channel, as well as CV Acute, its first immunity-support product that contains no CBD, a departure for the firm as it seeks new growth opportunities. More cannabis news in brief.